NCT00027586View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
MelanomaSkin Neoplasms
Interventions
DRUG

Imatinib mesylate (STI571)

400 mg twice a day orally

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00027586 - Imatinib Mesylate in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter